ReviewRecent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer2026
Advancements in Intraoperative Imaging for Enhanced Surgical Precision.
Review in Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The convergence of targeted imaging agents with intraoperative guidance systems is reshaping oncologic surgery to enable precision tumor resection and reduce residual disease. We examine the evolving role and integration of cancer theranostics with advanced image-guided intraoperative imaging to improve surgical precision and the targeted removal of diseased tissue while sparing normal vital structures. Molecularly engineered probes, for instance, the EGFR-targeted antibody conjugated with IRDye800CW and the folate receptor alpha-targeting agent, OTL38, delineate tumor margins with high sensitivity and specificity, and investigational tumor-targeting probes that combine preoperative PET imaging with real-time surgical navigation maximize tumor detection and removal for improving patient outcomes. These approaches exploit near-infrared (NIR) optical windows to overcome limitations at visible wavelengths, including shallow light penetration and autofluorescence, and enhance sensitivity and spatial resolution. In parallel, advances in imaging hardware and software have led to new artificial intelligence (AI)-powered surgical navigation devices, multispectral cameras, gamma probes, and Cerenkov luminescence systems that complement the molecular precision of these probes by offering enhanced depth detection and/or dynamic visualization. The integration of AI and augmented reality further refines image registration and quantitative analysis, ensuring that intraoperative feedback is accurate and actionable. The synthesis of molecular targeting and state-of-the-art imaging addresses the critical clinical need of achieving complete tumor resection, a key determinant of patient prognosis and recurrence. Recent Phase 2 and Phase 3 trials underscore the translational potential of these theranostic approaches, which are rapidly advancing toward routine practice. By enabling personalized and adaptive surgical strategies, the integration of cancer theranostics and intraoperative imaging represents a vital step forward in precision oncology, promising significant improvements in long-term patient outcomes.
Indexed as
Identifiers
42165837What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.